The Pharmacovigilance Risk Assessment Committee (PRAC) held their monthly meeting on 23-26 October 2017 and have since published the highlights on the EMA website.
In this meeting, as one safety referral reaches a conclusion. Zinbryta has been recommended with further restrictions due to its effects on the liver. Reviews on products containing hydroxyethyl-starch (for acute bleeding) and flupirtine (for acute pain) have begun this month.
To read the highlights from the monthly meeting, please click here.